Immunomedics CEO DeLuccia departs

Article

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, in June announced the resignation of Robert DeLuccia, the company’s president, CEO, and director. DeLuccia began his tenure at Immunomedics in June 1998, when he took over duties previously

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, in June announced the resignation of Robert DeLuccia, the company’s president, CEO, and director. DeLuccia began his tenure at Immunomedics in June 1998, when he took over duties previously handled by the company’s founder, Dr. David Goldenberg (SCAN 6/10/98). Dr. Goldenberg will resume the position of CEO, according to the company.

In other Immunomedics management moves, Philippe Barzin, general manager of Immunomedics Europe, will relocate to the company’s U.S. headquarters and assume the post of vice president for global marketing and business development.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.